Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
Authors:
- 1 May 2018
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 51 (5) , 733-738
Abstract
No abstract availableKeywords
Funding Information
- The Swedish Physicians Against AIDS Research Foundation (FOa2016-0009)
- Göteborg Medical Society (16/596971)
This publication has 22 references indexed in Scilit:
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyThe Journal of Infectious Diseases, 2014
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialThe Lancet Infectious Diseases, 2013
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING StudyThe Journal of Infectious Diseases, 2012
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyThe Lancet Infectious Diseases, 2012
- Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation ClassesThe Journal of Infectious Diseases, 2011
- Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected PatientsAntimicrobial Agents and Chemotherapy, 2010
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2008